Hints and tips:
Related Special Reports
...“You don’t want to focus on the same thing in two different places.”...
...Glass Lewis and ISS, which make recommendations to shareholders on how to vote at annual meetings and on matters of corporate governance, disputed the claim and urged investors to vote against the plan at...
...The British pharmaceutical company is preparing for a vote on its long-serving leader’s pay at the annual meeting on Thursday, including a rise that would take his package to a maximum of £18.7mn....
...AstraZeneca’s chair has hit out at proxy advisers for “double standards” that “do serious harm” to the competitiveness of UK companies, after more than a third of the company’s shareholders voted against...
...Unlike rivals Pfizer and BioNTech and Moderna, AstraZeneca initially adopted a non-profit model for its vaccine, selling it “at cost” as part of its agreement with Oxford, and the drug played a key role...
...Sedgwick will have to turn around flagging performance at the company....
...“There’s been a reduction of assets that don’t have the promise to be transformative medicines....
...Lecanemab is priced at $25,600 a year and is delivered via 38 infusions over an 18-month course....
...“We don’t think it’s going to be enormously damaging,” said Alessandro Valentini, a director of top-15 active GSK investor Causeway Capital Management. “We just want it to be done....
...But pharmaceutical companies can file several patents for single drugs at different times, delaying the entry of generic medicines....
...“What happens in a cirrhotic liver is [cells] don’t have that decision-making process any more to start dividing and restoring capacity....
...“The number of patients seeking care is so significant that we don’t see a lot of switching.”...
...Julien Dormois, an analyst at Jefferies, said the settlement was “much milder than feared”....
...It’s a drug that’s active against [resistant] pathogens that gives us a tool to treat the type of infection that we don’t have good options for now,” said Jay Purdy, Pfizer’s vice-president of global medical...
...While big pharma companies focus on developing innovative drugs that they can sell under patent and at high margins, recouping research and development costs, off-patent generic medicines such as methotrexate...
...“Wouldn’t it be great if you could turn those mechanisms off, or shift the microbiome away at an early time point where you’re now preventing those diseases, or pushing them off further in life, rather than...
...BioNTech [also] doesn’t have any other products so it’s a lot of cash to have to pay,” said Christopher Sharp, an IP lawyer at Pinsent Masons....
...Soriot said on Thursday that AstraZeneca’s deal activity would continue but “at a slower pace”....
...Sales at the company grew by 2.2 per cent to $1.4bn dollars, below analysts’ estimates, with the US accounting for almost half of total revenue....
...About 43 per cent of shareholders voted against the medical devices company’s proposals at its general meeting, which entailed Texas-based Deepak Nath receiving up to $11.8mn next year if all targets are...
...“Some of our loyal shareholders do expect cash dividends as an important part of total returns,” said AstraZeneca chair Michel Demaré at the AGM....
...Husain, a neurology professor at Oxford university....
...The Danish pharmaceutical company’s quarterly sales rose to DKr65bn ($9bn), an increase of 24 per cent at constant exchange rates, ahead of analysts’ estimates....
...These shifts have led some companies to remove the UK from their supply chains....
...Martin Holst Lange, head of development at Novo Nordisk, said that Cardior’s drug had the “potential to become a first-in-class therapy designed to halt or partially reverse the course of disease for people...
International Edition